{
    "clinical_study": {
        "@rank": "102471", 
        "acronym": "MV130", 
        "arm_group": [
            {
                "arm_group_label": "MV130", 
                "arm_group_type": "Experimental", 
                "description": "The subjects will receive daily dose of MV130 during 12 months"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The subjects will receive daily dose of placebo during 12 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the efficacy and safety of a biological vaccine\n      (MV130 in subjects with Chronic Obstructive Pulmonary Disease (COPD) compared with a placebo\n      group."
        }, 
        "brief_title": "Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Double blind parallel placebo controlled study. The subjects will receive medication during\n      12 months and will be followed up during another six months"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent.\n\n          -  Both gender\n\n          -  Age between 35 and 85.\n\n          -  Must be able to follow the treatment regimen\n\n          -  Diagnosis of moderate COPD according to GOLD criteria\n\n          -  Consumption of 10 or more packs of cigarettes/year\n\n          -  Fertile women of must use an approved contraceptive method\n\n        Exclusion Criteria:\n\n          -  Pregnant women, breastfeeding\n\n          -  Subject who has participated in a study or clinical trial with an investigational\n             product in the last 3 months before inclusion\n\n          -  Subject with severe COPD\n\n          -  Subject with a history of hypersensitivity to any component of the vaccine\n\n          -  Subject outside of age range\n\n          -  Subject diagnosed with asthma\n\n          -  Subject who has had an exacerbation 4 weeks before starting the trial.\n\n          -  Subject that have needed corticosteroids in the last 4 weeks before starting the\n             trial\n\n               -  Subject diagnosed with Primary or Secondary Immunodeficiency Subjects with\n                  chronic lymphoproliferative disease\n\n               -  Subjects with chronic infectious disease\n\n               -  Subject with chronic heart disease, arrhythmias, or episodes of arrhythmia\n                  secondary to the administration of bronchodilators.\n\n               -  Subject diagnosed with COPD and chronic colonization by Pseudomonas aeruginosa"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842360", 
            "org_study_id": "MV130-SLG-001", 
            "secondary_id": "2012-003253-28"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "The subjects will receive daily dose of placebo during 12 months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "MV130", 
                "description": "The subjects will receive daily dose of MV130 during 12 months", 
                "intervention_name": "MV130", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vaccine", 
            "Chronic obstructive pulmonary disease (COPD)"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jmiguel.hgugm@salud.madrid.org", 
                    "last_name": "Javier de Miguel, MD", 
                    "phone": "34915868000"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "Hospital General Universitario Gregorio Mara\u00f1\u00f3n"
                }, 
                "investigator": {
                    "last_name": "Javier de Miguel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jlaw@separ.es", 
                    "last_name": "Jos\u00e9 Luis \u00c1lvarez-Sala, MD-PhD- prof", 
                    "phone": "34913303045"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Hospital Cl\u00ednico San Carlos"
                }, 
                "investigator": {
                    "last_name": "Jos\u00e9 Luis Alvarez-Sala, MD-PhD-prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mbuendia.huil@salud.madrid.org", 
                    "last_name": "Mar\u00eda Jes\u00fas Buend\u00eda Garc\u00eda, MD", 
                    "phone": "34911918000"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28031"
                    }, 
                    "name": "Hospital Universitario Infanta Leonor"
                }, 
                "investigator": {
                    "last_name": "Buend\u00eda Mar\u00eda Jes\u00fas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Double-blind Placebo-controlled Prospective, Parallel, Multicentre Clinical Trial of Bacterial Vaccine Administered by Sublingual Mucosa in Subjects With COPD for Efficacy and Safety Evaluation and Immunomodulatory Response", 
        "overall_contact": {
            "email": "efernanedzc.hgugm@salud.madrid.org", 
            "last_name": "Eduardo Fern\u00e1ndez-Cruz, MD, PhD", 
            "phone": "34915868423"
        }, 
        "overall_contact_backup": {
            "email": "mcasanovas@inmunotek.com", 
            "last_name": "Miguel Casanovas, PhD; MD", 
            "phone": "34916510010"
        }, 
        "overall_official": [
            {
                "last_name": "Eduardo Fern\u00e1ndez-Cruz, MD-PhD-prof", 
                "role": "Study Director"
            }, 
            {
                "last_name": "Javier Miguel D\u00edez, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "last_name": "Jos\u00e9 Luis Alvarez-Salas, MD-PhD-prof,", 
                "role": "Principal Investigator"
            }, 
            {
                "last_name": "Mar\u00eda Jes\u00fas Buend\u00eda, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Decrease in the number of COP exacerbations.", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842360"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Severity of COPD exacerbations", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "First COPD exacerbation", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "The drugs consumption will be evaluated  as follows:\nAntibiotic: 1 point\nInhaled corticosteroids: 2 points\nSystemic corticosteroids: 3 points\nO2: 4 points\nVentilation: 5 points.", 
                "measure": "Use of drugs", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Number of visit to the doctor due to COPD exacerbations", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Number of visits to the emergency service", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Number of hospitalizations due to COPD exacerbations", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Days of hospitalization due to COPD exacerbations", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Changes from baseline in COPD Assessment Test (CAT)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Health costs during COPD exacerbations", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Specific Humoral Response (Serum immunoglobulin G against the vaccine bacterial antigens; salivary immunoglobulin A concentrations versus vaccine antigens) by ELISA.\nSpecific proliferative response of T cells (cluster of differentiation3 + / cluster of differentiation 4 + and cluster of differentiation 3 + / cluster of differentiation 8 +) in vitro following stimulation with bacterial antigens comprising the vaccine) by (carboxyfluorescein diacetate succinimidyl ester) CFSE labeling and flow cytometry.", 
                "measure": "Changes from baseline in immunological parameters", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 months"
            }, 
            {
                "measure": "Number of subjects with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Number of subjects with local reactions", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Inmunotek S.L.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Inmunotek S.L.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}